These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1496 related items for PubMed ID: 23953901

  • 1. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC, Easton JD, Hankey GJ, Hart RG.
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [Abstract] [Full Text] [Related]

  • 2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [Abstract] [Full Text] [Related]

  • 3. Novel oral anticoagulants in non-valvular atrial fibrillation.
    Potpara TS, Lip GY.
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
    [Abstract] [Full Text] [Related]

  • 4. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC, Weber R, Lip GY, Hohnloser SH.
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [Abstract] [Full Text] [Related]

  • 5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 6. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 7. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [Abstract] [Full Text] [Related]

  • 8. New oral anticoagulants in elderly patients.
    Barco S, Cheung YW, Eikelboom JW, Coppens M.
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.
    Clin Ther; 2014 Feb 01; 36(2):192-210.e20. PubMed ID: 24508420
    [Abstract] [Full Text] [Related]

  • 10. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.
    J Med Econ; 2014 Aug 01; 17(8):587-98. PubMed ID: 24831811
    [Abstract] [Full Text] [Related]

  • 11. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW.
    Hosp Pract (1995); 2011 Oct 21; 39(4):7-16. PubMed ID: 22056819
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.
    Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):480-6. PubMed ID: 22787066
    [Abstract] [Full Text] [Related]

  • 16. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP, Halperin JL.
    Hosp Pract (1995); 2013 Feb 01; 41(1):37-48. PubMed ID: 23466966
    [Abstract] [Full Text] [Related]

  • 17. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ.
    Postgrad Med; 2012 Nov 01; 124(6):7-16. PubMed ID: 23322134
    [Abstract] [Full Text] [Related]

  • 18. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.
    Am J Cardiol; 2012 Aug 01; 110(3):453-60. PubMed ID: 22537354
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.
    Value Health; 2013 Jun 01; 16(4):498-506. PubMed ID: 23796283
    [Abstract] [Full Text] [Related]

  • 20. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.
    J Med Econ; 2013 Sep 01; 16(9):1163-8. PubMed ID: 23869941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.